| abstract |
Disclosed is a therapeutic agent for gastrointestinal mucosal injury and a screening method thereof. Disclosed is a therapeutic agent for gastrointestinal mucosal injury having an action mechanism that inhibits signaling by IL-13. As an active ingredient of a therapeutic agent for gastrointestinal mucosa injury, IL-13Rα2 receptor protein or solubilized IL-13Rα2 protein, anti-IL-13 antibody, or a protein that binds to and inactivates IL-13, solubilized IL-13Rα1 Receptor, anti-IL-13Rα1 receptor antibody, IL-13Rα1 receptor antagonist, antisense oligonucleotide or siRNA against IL-13 precursor gene or IL-13Rα1 gene, aptamer against IL-13 or IL-13Rα1, etc. . The present invention also provides a method and a kit for screening a substance having a therapeutic effect on gastrointestinal mucosal injury. [Selection] Figure 11 |